


## PAP-1

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 870653-45-5   |
| Formula:          | C <sub>21</sub> H <sub>18</sub> O <sub>5</sub>  |
| Molecular Weight: | 350.36  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|                            |   |
|----------------------------|---|
| Description                | PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a selective, orally active Kv1.3 blocker with an EC <sub>50</sub> of 2 nM.   |
| Targets(IC <sub>50</sub> ) | Potassium Channel   |
| In vitro                   | PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC <sub>50</sub> : 45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels [1, 2]. PAP-1 (2-100 nM; 30 minutes) suppresses the proliferation of CCR7-TEM cells (IC <sub>50</sub> : 10 nM) [1]. |
| In vivo                    | PAP-1 (0.3-3 mg/kg; i.p.; thrice daily for 48 hours) prevents delayed type hypersensitivity (DTH) in Lewis rats [1].  |
| Cell Research              | Cell Line: CCR7-TEM cells (anti-CD3 Ab stimulated). Concentration: 2, 10, 25, 100 nM. Incubation Time: 30 minutes [1]   |
| Animal Research            | Animal Model: 9- to 11- week-old female Lewis rats. Dosage: I.P.; three times daily for 48 hours. Administration: 0.3, 1, 3 mg/kg [1]   |

## Solubility Information

|                     |   |
|---------------------|---|
| Solubility          | DMSO: 50 mg/mL (142.71 mM), Sonication is recommended.<br>H <sub>2</sub> O: Insoluble,<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)   |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.71 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 2.8542 mL | 14.271 mL | 28.5421 mL |
| 5 mM  | 0.5708 mL | 2.8542 mL | 5.7084 mL  |
| 10 mM | 0.2854 mL | 1.4271 mL | 2.8542 mL  |
| 50 mM | 0.0571 mL | 0.2854 mL | 0.5708 mL  |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Schmitz A, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. *Mol Pharmacol.* 2005 Nov;68(5):1254-70.

Chen Y, Zhi Y, Zhong H, et al. Inhibition of Kv1.3 channel restrains macrophage M2 polarization and ameliorates renal fibrosis via regulating STAT6 phosphorylation. *Pharmacological Research.* 2025: 107623.

Pereira LE, et al. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. *Exp Biol Med (Maywood).* 2007 Nov;232(10):1338-54.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481